Monitor the Form 10 registration statement filing for details on capital structure, asset allocation, and dividend policies of each entity. The separation timeline through H1 2028 means execution risk and regulatory approvals will be key milestones.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 4 $79.96entry
- T+1 · 12d ago +1.71%α +6.12% · $81.33
- T+5 · 6d ago +11.96%α +12.87% · $89.52
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CVS Health announced plans to separate into two independent publicly traded companies: a healthcare solutions company (Aetna, Caremark, Oak Street Health, Signify Health) and a retail pharmacy company (CVS Pharmacy, MinuteClinic, Health100). The tax-free separation is expected to close in the first half of 2028. The company also separately announced Q3 2026 results and raised full-year 2026 guidance.
Key Facts
- CVS Health intends to separate into two independent, publicly traded companies: a healthcare solutions company (Aetna, CVS Caremark, CVS Specialty, Oak Street Health, Signify Health) and a retail pharmacy company (CVS Pharmacy, MinuteClinic, Health100).
- The separation is intended to be tax-free to CVS Health and its shareholders for U.S. federal income tax purposes.
- Expected completion in the first half of 2028, subject to Board approval, SEC Form 10 effectiveness, and tax confirmation.
- David Joyner will be Chairman and CEO of the healthcare solutions company; Prem Shah will be CEO of CVS Pharmacy.
- Both companies are expected to have a solid investment grade rating, strong free cash flow, and an attractive dividend.
- CVS Health separately announced Q3 2026 results and raised full-year 2026 guidance in a concurrent press release.
- Goldman Sachs & Co. LLC is lead financial advisor; Wachtell, Lipton, Rosen & Katz is legal counsel.
Financial Impact
No financial terms or valuations disclosed for the separation. The filing references Q3 2026 results and raised full-year 2026 guidance in a separate release, but no specific figures are provided in this document.
Risk Factors
- Separation may not be completed on the announced timeline or at all due to regulatory, tax, or Board approval conditions.
- Expected tax-free treatment may not be confirmed, creating potential tax liability for shareholders.
- Dis-synergy costs and restructuring expenses could exceed estimates, impacting near-term financials.
- The separation could distract management from operational execution during the transition period.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-446150 |
| Document: d148827dex991.htm | 0001193125-26-446150 |
| Document: 0001193125-26-446150-index-headers.html | 0001193125-26-446150 |
| Document: 0001193125-26-446150-index.html | 0001193125-26-446150 |
| Document: 0001193125-26-446150.txt | 0001193125-26-446150 |
Track record
25 reports on CVS
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +32.33% at T+60 after the Apr 8, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 13, 20264d ago Court Ruling Neutral 3/10 No price data
- Nov 6, 202610d ago Insider Buy Bullish 4/10 Entry $85.25 Now $88.59 +3.92% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 6/10 Viewing Entry $79.96 Now $88.59 +10.79% settles Dec 3
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $79.96 Now $88.59 +10.79% settles Dec 3
- Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $92.53 Now $88.59 −4.26% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 2/10 Entry $92.58 to $89.79 Now $88.59 −4.31% ▼ −3.01% −1.11% vs SPY
- Sep 30, 20266w ago Press Release Neutral 2/10 Entry $85.20 to $90.33 Now $88.59 +3.98% ▲ +6.02% +5.32% vs SPY
- Aug 5, 202614w ago 8-K Bullish 8/10 Entry $99.12 to $97.23 Now $88.59 −10.62% ▼ −1.91% −1.31% vs SPY
- Jul 10, 202618w ago Press Release Neutral 2/10 Entry $104.15 to $95.46 Now $88.59 −14.94% ▼ −8.35% −10.77% vs SPY
- Jun 29, 202620w ago Court Ruling Bullish 5/10 Entry $103.58 to $107.74 Now $88.59 −14.47% ▲ +4.02% +4.30% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers